$0.69
-0.0098[-1.40%]
At close: Apr 26
$0.69
0[0.00%]
After Hours: 6:49PM EDT
Atara Biotherapeutics
(NASDAQ:ATRA)Latest News for Atara Biotherapeutics Stock (NASDAQ:ATRA)
Atara Biotherapeutics Stock (NASDAQ: ATRA)
Categories: All
Monday, April 08, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
Monday, March 18, 2024
Friday, March 08, 2024
Wednesday, March 06, 2024
Thursday, February 29, 2024
Wednesday, February 14, 2024
Monday, February 05, 2024
Friday, February 02, 2024
Thursday, February 01, 2024
- Atara Biotherapeutics shares are trading higher after the company and Pierre Fabre Laboratories announced the publication of Phase 3 ALLELE Tab-cel data.Benzinga Newsdesk - Feb 1, 2024, 2:38PM
- Reported Late Wednesday, Atara Biotherapeutics And Pierre Fabre Laboratories Announced The Publication Of Phase 3 ALLELE Tab-CelĀ® Data In The Lancet OncologyBenzinga Newsdesk - Feb 1, 2024, 3:17AM
Monday, January 15, 2024
Monday, January 08, 2024
- Atara Biotherapeutics shares are trading higher. The company announced that it entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at $0.55 per pre-funded warrant share in a $15 million registered direct offering.Benzinga Newsdesk - Jan 8, 2024, 3:26PM
- Atara Biotherapeutics Enters Agreement For Issuance And Sale Of Pre-Funded Warrants To Purchase 27,272,727 Shares Of Common Stock At $0.55 Per Pre-Funded Warrant Share In $15M Registered Direct OfferingBenzinga Newsdesk - Jan 8, 2024, 9:19AM
Monday, December 25, 2023
Friday, December 22, 2023
Thursday, December 21, 2023
Wednesday, December 20, 2023
- Atara Biotherapeutics shares are trading higher after the company announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel.Benzinga Newsdesk - Dec 20, 2023, 4:40PM
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga Insights - Dec 20, 2023, 4:31PM
- Atara Biotherapeutics Announced The Closing Of The Expanded Global Partnership With Pierre Fabre Laboratories For TabelecleucelBenzinga Newsdesk - Dec 20, 2023, 4:05PM
Monday, December 11, 2023
Thursday, December 07, 2023
Thursday, November 30, 2023
Friday, November 10, 2023
Thursday, November 09, 2023
- Dow Falls Over 200 Points; Krispy Kreme Reports Downbeat ResultsLisa Levin - Nov 9, 2023, 2:45PM
- Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Nov 9, 2023, 1:13PM
- Atara Biotherapeutics shares are trading lower after the company announced the primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis did not meet the primary endpoint of confirmed disability improvement. Also, multiple firms downgraded the stock.Benzinga Newsdesk - Nov 9, 2023, 12:37PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Nov 9, 2023, 12:31PM
- Crude Oil Rises Over 1%; Tapestry Posts Upbeat EarningsLisa Levin - Nov 9, 2023, 12:01PM
- US Stocks Mostly Flat; Jobless Claims Decline In Latest WeekLisa Levin - Nov 9, 2023, 9:43AM
- Evercore ISI Group Downgrades Atara Biotherapeutics to In-LineBenzinga Newsdesk - Nov 9, 2023, 9:38AM
- Why AppLovin Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving PremarketLisa Levin - Nov 9, 2023, 9:29AM
- Why Atara Biotherapeutics Shares Are Plummeting TodayNabaparna Bhattacharya - Nov 9, 2023, 8:09AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Nov 9, 2023, 8:06AM
- HC Wainwright & Co. Downgrades Atara Biotherapeutics to NeutralBenzinga Newsdesk - Nov 9, 2023, 7:46AM
- Mizuho Downgrades Atara Biotherapeutics to Neutral, Lowers Price Target to $1Benzinga Newsdesk - Nov 9, 2023, 7:13AM
Wednesday, November 08, 2023
- Atara Biotherapeutics Announces Primary Analysis Data From Phase 2 EMBOLD Clinical Trial Of ATA188 In Non-Active Progressive Multiple Sclerosis; Primary Endpoint Of Confirmed Disability Improvement At 12 Months Not AchievedBenzinga Newsdesk - Nov 8, 2023, 6:04PM
- Atara Biotherapeutics Halted, Pending NewsCharles Gross - Nov 8, 2023, 5:26PM
Wednesday, November 01, 2023
- Atara Biotherapeutics May Offer, Sell, From Time To Time Common Shares Par Value $0.0001 Per Share With Offering Price Of Up To $100MCharles Gross - Nov 1, 2023, 4:57PM
- Atara Biotherapeutics Q3 EPS $(0.66), Inline, Sales $2.14M Miss $4.76M EstimateBenzinga Newsdesk - Nov 1, 2023, 8:43AM
- Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership With Pierre Fabre Laboratories And Third Quarter 2023 Financial Results; Cash, Cash Equivalents And Short-Term Investments As Of September 30, 2023, Totaled $102.4MBenzinga Newsdesk - Nov 1, 2023, 8:34AM